"We still believe that Sepracor is a good new product story with two products (Lunesta and Xopenex MDI) early in their life cycles and another product (arformoterol) expected to launch in 2007," the analyst added. ❋ Unknown (2006)
Goodman believes that investors will increasingly return to Sepracor as its Lunesta sleep-aid continues its ramp in the face of new product launches, Xopenex franchise continues to grow, and arformoterol is approved by year-end 2006 or early 2007. ❋ Unknown (2006)
Approval for respiratory drug arformoterol could spark additional gains, the analyst added. ❋ Unknown (2006)
According to investigators, Medicare paid for 7 million units of the drug arformoterol, even though the manufacturer and the three largest wholesalers sold only 750,000 units in the area in 2008 and the first half of 2009. ❋ Unknown (2010)
The spike in arformoterol only came after authorities tried to crack down on another inhaler drug, and illustrates a constant problem plaguing investigators. ❋ Unknown (2010)
Fraudulent providers quickly realized they couldn't get as much money for that drug and began billing Medicare for arformoterol at rates exceeding the amount of drugs available. ❋ Unknown (2010)
BROVANA® brand arformoterol tartrate Inhalation Solution, OMNARIS ™ brand ciclesonide Nasal Spray and ❋ Unknown (2008)
In fact, the high-dose arformoterol group showed somewhat greater reductions in rescue and supplemental medication use at six months than during the first few weeks of treatment. ❋ Unknown (2008)
Steven Brown, M.D., a pulmonologist in Glendale, Wis., called the findings reassuring, especially in light of the black-box warning on arformoterol and all other products containing long-acting beta agonists. ❋ Unknown (2008)
The values for arformoterol after six months were 0.24 L for the higher dose and 0.20 L for the lower dose, slightly lower than at the trial's start. ❋ Unknown (2008)
Explain to interested patients that the study identified no major safety concerns with arformoterol (Brovana) either at the currently approved dose or at a higher dose. ❋ Unknown (2008)
Other analyses of adverse events showed no differences between arformoterol and formoterol, or between the two arformoterol doses. ❋ Unknown (2008)
Declines in use of rescue and supplemental medications were also largely maintained, more so with the two arformoterol groups than with formoterol. ❋ Unknown (2008)
PHILADELPHIA, Oct. 30 -- No safety concerns and no loss of efficacy were seen in a six-month study of nebulized arformoterol (Brovana), a long-acting beta agonist for chronic obstructive pulmonary disease. ❋ Unknown (2008)
Dr. Hanania said the study was prompted by concerns about the safety of long-acting beta agonists including arformoterol, particularly in nebulized formulations. ❋ Unknown (2008)
Serious adverse events were seen in 6. 8\% of patients in the high-dose arformoterol group and ❋ Unknown (2008)
Currently marketed products include LUNESTA® brand eszopiclone, XOPENEX® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA® brand levalbuterol tartrate Inhalation Aerosol, BROVANA® brand arformoterol tartrate Inhalation Solution, OMNARIS® brand ciclesonide Nasal Spray and ALVESCO® brand ciclesonide HFA Inhalation Aerosol. ❋ Unknown (2010)
High-dose arformoterol appeared to be slightly more effective in this respect than formoterol or low-dose arformoterol ( ❋ Unknown (2008)
